Literature DB >> 21338678

Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells.

Steven C Derrick1, Idalia M Yabe, Amy Yang, Sheldon L Morris.   

Abstract

The development of improved vaccines against Mycobacterium tuberculosis has been hindered by a limited understanding of the immune correlates of anti-tuberculosis protective immunity. In this study, we examined the relationship between long-term anti-tuberculosis protection and the mycobacterial-specific CD4 multifunctional T (MFT) cell responses induced by five different TB vaccines (live-attenuated, subunit, viral vectored, plasmid DNA, and combination vaccines) in a mouse model of pulmonary tuberculosis. In a 14-month experiment, we showed that TB vaccine-induced CD4 T cell responses were heterogenous. Antigen-specific monofunctional CD4 T cells expressing single cytokines and MFT CD4 T cells expressing multiple cytokines (IFN-γ and TNF-α, IFN-γ and IFN-γ, TNF-α, and IL-2, and all three cytokines) were identified after the immunizations. Interestingly, compared to the monofunctional cells, significantly higher median fluorescent intensities (MFIs) for IFN-γ and TNF-α were detected for triple-positive MFT CD4 T cells induced by the most protective vaccines while modest differences in relative MFI values were seen for the less protective preparations. Most importantly during the 14-month study, the levels of vaccine-induced pulmonary and splenic protective immunity correlated with the frequency and the integrated MFI (iMFI, frequency×MFI) values of triple-positive CD4 T cells that were induced by the same vaccines. These data support efforts to use MFT cell analyses as a measure of TB vaccine immunogenicity in human immunization studies. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21338678     DOI: 10.1016/j.vaccine.2011.02.010

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  63 in total

1.  Tuberculosis vaccine promises sterilizing immunity.

Authors:  Helen McShane; Ann Williams
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

2.  Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Authors:  A B B Macedo; J C Sánchez-Arcila; A O Schubach; S C F Mendonça; A Marins-Dos-Santos; M de Fatima Madeira; T Gagini; M I F Pimentel; P M De Luca
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

3.  Use of antigen-specific interleukin-2 to differentiate between cattle vaccinated with Mycobacterium bovis BCG and cattle infected with M. bovis.

Authors:  Shelley G Rhodes; Lucy C McKinna; Sabine Steinbach; Gilly S Dean; Bernardo Villarreal-Ramos; Adam O Whelan; C Pirson; Gareth J Jones; Derek Clifford; H Martin Vordermeier
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

4.  COMPASS identifies T-cell subsets correlated with clinical outcomes.

Authors:  Lin Lin; Greg Finak; Kevin Ushey; Chetan Seshadri; Thomas R Hawn; Nicole Frahm; Thomas J Scriba; Hassan Mahomed; Willem Hanekom; Pierre-Alexandre Bart; Giuseppe Pantaleo; Georgia D Tomaras; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Nelson L Michael; Jerome H Kim; Merlin L Robb; Robert J O'Connell; Nicos Karasavvas; Peter Gilbert; Stephen C De Rosa; M Juliana McElrath; Raphael Gottardo
Journal:  Nat Biotechnol       Date:  2015-05-25       Impact factor: 54.908

5.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

6.  Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.

Authors:  Daniel O Villarreal; Jewell Walters; Dominick J Laddy; Jian Yan; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Quest for correlates of protection against tuberculosis.

Authors:  Kamlesh Bhatt; Sheetal Verma; Jerrold J Ellner; Padmini Salgame
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

8.  A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection.

Authors:  Hongmei Kong; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

9.  Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.

Authors:  Ming Zhang; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

10.  Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination.

Authors:  Han Kang; Qin Yuan; Hui Ma; Zhi-Dong Hu; De-Ping Han; Kang Wu; Douglas B Lowrie; Xiao-Yong Fan
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.